Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Study Links Obesity-Driven Fatty Acids To Breast Cancer, Warns Against High-Fat Diets Like Keto

October 22nd 2025

A study suggests that breast cancer patients with obesity could benefit from lipid lowering therapies and should avoid high-fat weight loss regimens.

DSMB Recommends Continuation of Phase 3 Study of Bria-IMT in Metastatic Breast Cancer

October 22nd 2025

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.

Metastatic Breast Cancer 2025 UPDATE

October 20th 2025

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

Sacituzumab Govitecan Plus Pembrolizumab Upholds QOL, Delays Physical Decline in mTNBC

October 20th 2025

Sacituzumab govitecan plus pembrolizumab may maintain quality of life in patients with previously untreated, PD-L1–positive metastatic TNBC.

Dr Hurvitz on Sustained Benefit With Adjuvant Ribociclib Plus AI Therapy in HR+/HER2– Breast Cancer

October 19th 2025

Sara A. Hurvitz, MD, FACP, shares 5-year efficacy updates from the phase 3 NATALEE trial in HR-positive HER2-negative breast cancer.

Dr Mayer on Efficacy Data With Giredestrant Plus Everolimus in ER+/HER2– Breast Cancer

October 19th 2025

Erica L. Mayer, MD, MPH, discusses primary efficacy outcomes for giredestrant in the phase 3 evERA trial in ER-positive, HER2-negative advanced breast cancer.

Sacituzumab Govitecan Reduces Risk of Progression or Death by 38% in PD-1/PD-L1–Ineligible TNBC

October 19th 2025

Sacituzumab govitecan reduced the risk for disease progression or death by 38% vs chemotherapy in previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer.

Gedatolisib Plus Fulvestrant ± Palbociclib Drives PFS Improvement in PIK3CA Wild-Type, HR+/HER2– Advanced Breast Cancer

October 19th 2025

Gedatolisib plus fulvestrant, with or without palbociclib, improved PFS in pretreated, HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer

October 19th 2025

Sac-TMT bested chemotherapy in terms of PFS in previously treated HR+, HER2– metastatic breast cancer.

Giredestrant/Everolimus Extends PFS for ER+, HER2– Advanced Breast Cancer

October 18th 2025

Giredestrant plus everolimus improved progression-free survival in ER-positive, HER2-negative advanced breast cancer after a prior CDK4/6 inhibitor.

Adjuvant Ribociclib Plus AI Therapy Has Long-Term Activity in HR+, HER2-Negative Early Breast Cancer

October 17th 2025

Adjuvant ribociclib plus an aromatase inhibitor was safe and displayed long-term efficacy in hormone receptor–positive, HER2-negative early breast cancer.

Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer

October 17th 2025

The addition of adjuvant abemaciclib to endocrine therapy provided an OS benefit vs endocrine therapy alone in hormone receptor–positive breast cancer.

Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews

October 13th 2025

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

Five Under 5: Top Oncology Videos for the Week of 10/5

October 12th 2025

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 10/5

October 11th 2025

The FDA approved adjuvant cemiplimab in cutaneous squamous cell carcinoma, issued a CRL to dasatinib in chronic myeloid leukemia, and more.

Dr LeVee on Limitations of the ASCENT-04 Trial of Sacituzumab Govitecan Plus Pembrolizumab in TNBC

October 6th 2025

Alexis LeVee, MD, discusses the clinical implications of the ASCENT-04 trial data for patients with TNBC who relapse following prior PD-1 or PD-L1 therapy.

First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC

October 6th 2025

Dato-DXd displayed topline survival benefits in patients with recurrent/metastatic TNBC who could not receive immunotherapy.

OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025

October 3rd 2025

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

Case Study Highlights Tumor Burden Reduction With Paxalisib Combo in Metastatic TNBC

October 3rd 2025

Paxalisib plus pembrolizumab and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer.

OncLive’s September Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 3rd 2025

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.